Neurotech International Archives | Cannabiz

Neurotech results could lead to treatment alternatives for range of neuroinflammatory disorders

by Martin Lane June 10, 2022June 10, 2022

Neurotech International (NTI) has announced preclinical research results demonstrating its proprietary cannabis strain NTI164 can improve […]

Company news: ANTG; Avecho; Canopy Growth; Zelira/Levin Health; Neurotech; Epsilon; Creso Pharma

by cannabiz team December 9, 2021December 9, 2021

More positive results for Neurotech’s MS treatment

by Martin Lane July 8, 2021July 14, 2021

Neurotech offers hope for MS sufferers

by Martin Lane May 26, 2021May 27, 2021

Neurotech International

Company news: Neurotech International; MGC Pharma; Creso Pharma; Zelira Therapeutics; Ecofibre

by Martin Lane May 5, 2021May 7, 2021

Neurotech secures cultivation partnership with CannaPacific

by Martin Lane March 10, 2021March 10, 2021

Neurotech extends licence to include all neurological disorders

by Martin Lane March 3, 2021March 3, 2021

Neurotech International

Neurotech to conduct autism trial

by Martin Lane February 17, 2021February 17, 2021

Neurotech International

Neurotech International completes in-vitro studies of its proprietary cannabis leads, clinical trials to follow

by Martin Lane December 22, 2020December 22, 2020

Mente autism

Neurotech International’s new chairman to focus on cannabis treatments for cognitive disorders

by Emma Castle November 2, 2020November 2, 2020